OBJECTIVE: To study the impact of the 79A>C polymorphism in the cytidine deaminase (CDA) gene on the pharmacokinetics of gemcitabine and its metabolite 2',2'-difluorodeoxyuridine (dFdU) in non-small-cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: Patients (n = 20) received gemcitabine 1,125 mg/m(2) as a 30 min i.v. infusion as part of treatment for NSCLC. Plasma samples were collected during 0-6 h after gemcitabine administration. Gemcitabine and dFdU were quantified by high performance liquid chromatography with ultraviolet detection. The CDA 79A>C genotype was determined with PCR and DNA sequencing. RESULTS: Gemcitabine was rapidly cleared from plasma and undetectable after 3 h. The allele frequency of the 79A>C polymorphism was 0.40. Diplotypes were distributed as A/A n = 8, A/C n = 8 ,and C/C n = 4. No significant differences were found between the different CDA genotypes and gemcitabine or dFdU AUC, clearance, or half-life. CONCLUSION: The 79A>C polymorphism in the CDA gene does not have a major consistent and signficant impact on gemcitabine pharmacokinetics.
OBJECTIVE: To study the impact of the 79A>C polymorphism in the cytidine deaminase (CDA) gene on the pharmacokinetics of gemcitabine and its metabolite 2',2'-difluorodeoxyuridine (dFdU) in non-small-cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: Patients (n = 20) received gemcitabine 1,125 mg/m(2) as a 30 min i.v. infusion as part of treatment for NSCLC. Plasma samples were collected during 0-6 h after gemcitabine administration. Gemcitabine and dFdU were quantified by high performance liquid chromatography with ultraviolet detection. The CDA 79A>C genotype was determined with PCR and DNA sequencing. RESULTS:Gemcitabine was rapidly cleared from plasma and undetectable after 3 h. The allele frequency of the 79A>C polymorphism was 0.40. Diplotypes were distributed as A/A n = 8, A/C n = 8 ,and C/C n = 4. No significant differences were found between the different CDA genotypes and gemcitabine or dFdU AUC, clearance, or half-life. CONCLUSION: The 79A>C polymorphism in the CDA gene does not have a major consistent and signficant impact on gemcitabine pharmacokinetics.
Authors: P F Conte; A Gennari; S Donati; B Salvadori; E Baldini; C Bengala; I Pazzagli; C Orlandini; R Danesi; S Fogli; M Del Tacca Journal: Breast Cancer Res Treat Date: 2001-07 Impact factor: 4.872
Authors: Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson Journal: N Engl J Med Date: 2002-01-10 Impact factor: 91.245
Authors: Carmelo Tibaldi; Elisa Giovannetti; Enrico Vasile; Valentina Mey; Adrie C Laan; Sara Nannizzi; Roberta Di Marsico; Andrea Antonuzzo; Cinzia Orlandini; Simona Ricciardi; Mario Del Tacca; Godefridus J Peters; Alfredo Falcone; Romano Danesi Journal: Clin Cancer Res Date: 2008-03-15 Impact factor: 12.531
Authors: J R Mackey; R S Mani; M Selner; D Mowles; J D Young; J A Belt; C R Crawford; C E Cass Journal: Cancer Res Date: 1998-10-01 Impact factor: 12.701
Authors: F M Wachters; J W G Van Putten; H Kramer; Z Erjavec; P Eppinga; J H Strijbos; G P J de Leede; H M Boezen; E G E de Vries; H J M Groen Journal: Br J Cancer Date: 2003-10-06 Impact factor: 7.640